12:00 AM
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lorvotuzumab mertansine: Phase I data

Data from 33 patients with advanced solid tumors in the dose-escalation Phase I portion of the open-label, international Phase I/II NORTH trial showed that IMGN901 plus etoposide and carboplatin led to 10 objective responses, including 6 responses in 13 evaluable SCLC patients. The disease control rate (DCR) was 72.7%. The...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >